Jessica A. Cohen

Jessica A. Cohen

Auto-generated profile, based on publicly available information

Jessica A. Cohen

PATH, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
JCJessica A. Cohen
Jessica A. Cohen
MSMatthew S. Steele
Matthew S. Steele
FUFrancisco I. Cáceres Ureña
Francisco I. Cáceres Ureña
MBMags E. Beksinska
Mags E. Beksinska
The objectives of this study were to prioritize applicator design attributes among women in the Dominican Republic and South Africa, and to determine how preferences differed based on sociodemographic variables. The goal was to identify acceptable microbicide applicator designs in 2 low-resource settings. We surveyed 895 women, randomly sampled from clinics in the Dominican Republic (n = 449) and South Africa (n = 446), with questions on sociodemographics, applicator attribute preferences, and price/design tradeoffs. Single-use design was the most valued attribute, and reusable design and low price were the least valued attributes in both populations. Preference for single-use design was associated with concern about reusable applicators spreading germs, secondary or higher education, older age, having children, and perception of moderate to high HIV risk. Acceptability factors related to microbicide delivery mechanisms should continue to be evaluated among potential microbicide users to directly inform product development and introduction of microbicides.

1 January 2005 in Reproductive Health Matters
Verified
Journal Article
Open access
JCJessica Cohen
Jessica Cohen
OOOlivia Ortiz
Olivia Ortiz
SLSilvia Elena Llaguno
Silvia Elena Llaguno
LGLorelei Goodyear
Lorelei Goodyear
DBDeborah Billings
Deborah Billings
IMImelda Martinez
Imelda Martinez
In Latin America, where restrictive laws limit women's access to safe abortion services, misoprostol is being used to induce abortions, often without correct information on dosage or regimens. This study in an unnamed Latin American country aimed to identify appropriate channels through which instructions on misoprostol use could be disseminated to women. In-depth interviews were carried out with physicians, pharmacy staff, women who had had safe abortions and women from the community, as well as focus group discussions with advocates of safe abortion. Participants considered physicians to be the most appropriate source of information and for ensuring confidentiality for both women and provider. Participants considered midwives, pharmacists and women's groups as appropriate referral points, but not providers of information. Legal restrictions and professional risk were the primary reasons why pharmacists rejected this role, though many are selling misoprostol. There was a general lack of information about misoprostol for medical abortion among both health professionals and women. Accurate information about misoprostol use for a wide range of gynaecologic and obstetric purposes, including induced abortion, could be incorporated into training and educational materials for physicians, midwives and other appropriate mid-level providers, as well as pharmacists. Without these alternative information channels, access to information would be severely restricted, especially in rural areas.

1 June 2013 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
JCJessica A. Cohen
Jessica A. Cohen
VBVivian Brache
Vivian Brache
JFJennifer Foster
Jennifer Foster
LCLeila Cochon
Leila Cochon
MCMarianne Callahan
Marianne Callahan
JSJill Schwartz
Jill Schwartz
A bridging study was performed to compare the safety, dose delivery, and acceptability of a prefilled plastic and user-filled paper applicator to assess whether a low-cost, user-filled, paper applicator could serve as a delivery option for tenofovir (TFV) 1% vaginal microbicide gel. The study used a randomized crossover design with 25 healthy women randomized to begin with the prefilled or user-filled applicator. Within each study arm, participants delivered two 4.0-mL doses of TFV 1% gel vaginally for 7 days, with one dose delivered at the clinic each morning and a second dose delivered at home each evening. To assess the primary objective, applicator safety, colposcopy examinations were performed at 2 time points in each study arm. There were no colposcopic findings or adverse events attributable to either applicator. One case of vulvovaginal candidiasis was considered possibly related to gel use. On average, the user-filled applicator delivered 96% of the target dose, with 85% of doses falling within ± 10% of the average dose volume. Participants found both applicators comparable for ease of use, insertion, and dispensing gel, with 60% of participants preferring the user-filled applicator. This study suggests that both applicators are safe, and most women delivered TFV with the user-filled applicator as directed. Participants found both applicators acceptable, with a slight majority preferring the user-filled applicator. Incorporating a low-cost, user-filled, paper applicator to deliver TFV could help reduce costs and improve access to TFV 1% gel, especially in resource-limited settings heavily impacted by HIV.

22 July 2014 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
JCJessica A. Cohen
Jessica A. Cohen
AMAnna C. Mastroianni
Anna C. Mastroianni
RMRuth Macklin
Ruth Macklin